Botanisol Analytics Performs Validation Process of Rapid Digital COVID-19 Screener with Leading Hospital
Share Article
Beth Israel Deaconess Medical Center generates data and expands capabilities of device with machine learning to detect SARS-CoV-2
Analytics 785+ System
While current disease screening equipment relies on a complicated, slow supply chain of scientists and chemical laboratories, the future of medical triage is automated, everywhere, and operates at the speed of light. We're proud to partner with leading institutions to realize that exciting future.
BOSTON (PRWEB)
February 24, 2021
Botanisol Analytics, a cutting-edge biological threat detection technology company, is performing, under a sponsored research agreement, a pre-clinical study with Beth Israel Deaconess Medical Center (BIDMC), an academic medical center affiliated with Harvard Medical School (HMS), that was designed to validate its rapid digital pathogen screening system for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.